Androgen-repressed phenotype in human prostate cancer

Hai Yen E Zhau, Shi Ming Chang, Bao Qi Chen, Yunling Wang, Hongquan Zhang, Chinghai Kao, Qingxiang Amy Sang, Sen J. Pathak, Leland W K Chung

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

An androgen-repressed human prostate cancer cell line, ARCaP, was established and characterized. This cell line was derived from the ascites fluid of a patient with advanced metastatic disease. In contrast to the behavior of androgen-dependent LNCaP and its androgen-independent C4-2 subline, androgen and estrogen suppress the growth of ARCaP cells in a dose- dependent manner in vivo and in vitro. ARCaP is tumorigenic and highly metastatic. It metastasizes to the lymph node, lung, pancreas, liver, kidney, and bone, and forms ascites fluid in athymic hosts. ARCaP cells express low levels of androgen receptor mRNA and prostate-specific antigen mRNA and protein. Immunohistochemical staining shows that ARCaP cells stain intensely for epidermal growth factor receptor, c-erb B2/neu, and c-erb B3. Staining is negative for chromogranin A and positive for bombesin, serotonin, neuron- specific enolase, and the c-met protooncogene (a hepatic growth factor/scatter factor receptor). ARCaP cells also secrete high levels of gelatinase A and B and some stromelysin, which suggests that this cell line may contain markers representing invasive adenocarcinoma with selective neuronendocrine phenotypes. Along with its repression of growth, androgen is also found to repress the expression of prostate-specific antigen in ARCaP cells as detected by a prostate-specific antigen promoter-β-galactosidase reporter assay. Our results suggest that the androgen-repressed state may be central to prostate cancer progression and that advanced prostate cancer can progress from an androgen-independent to an androgen-repressed state.

Original languageEnglish (US)
Pages (from-to)15152-15157
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume93
Issue number26
DOIs
StatePublished - Dec 24 1996
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Phenotype
Prostate-Specific Antigen
Ascites
Cell Line
Galactosidases
Proto-Oncogene Proteins c-met
Chromogranin A
Bombesin
Negative Staining
Matrix Metalloproteinase 3
Messenger RNA
Phosphopyruvate Hydratase
Liver
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Androgen Receptors
Growth
Epidermal Growth Factor Receptor

Keywords

  • androgen receptor
  • bone metastasis
  • gene expression
  • metalloproteinases
  • prostate-specific antigen

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Androgen-repressed phenotype in human prostate cancer. / Zhau, Hai Yen E; Chang, Shi Ming; Chen, Bao Qi; Wang, Yunling; Zhang, Hongquan; Kao, Chinghai; Sang, Qingxiang Amy; Pathak, Sen J.; Chung, Leland W K.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, No. 26, 24.12.1996, p. 15152-15157.

Research output: Contribution to journalArticle

Zhau, HYE, Chang, SM, Chen, BQ, Wang, Y, Zhang, H, Kao, C, Sang, QA, Pathak, SJ & Chung, LWK 1996, 'Androgen-repressed phenotype in human prostate cancer', Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 26, pp. 15152-15157. https://doi.org/10.1073/pnas.93.26.15152
Zhau, Hai Yen E ; Chang, Shi Ming ; Chen, Bao Qi ; Wang, Yunling ; Zhang, Hongquan ; Kao, Chinghai ; Sang, Qingxiang Amy ; Pathak, Sen J. ; Chung, Leland W K. / Androgen-repressed phenotype in human prostate cancer. In: Proceedings of the National Academy of Sciences of the United States of America. 1996 ; Vol. 93, No. 26. pp. 15152-15157.
@article{a88d991f85bb4e8bbf971956fa3b868a,
title = "Androgen-repressed phenotype in human prostate cancer",
abstract = "An androgen-repressed human prostate cancer cell line, ARCaP, was established and characterized. This cell line was derived from the ascites fluid of a patient with advanced metastatic disease. In contrast to the behavior of androgen-dependent LNCaP and its androgen-independent C4-2 subline, androgen and estrogen suppress the growth of ARCaP cells in a dose- dependent manner in vivo and in vitro. ARCaP is tumorigenic and highly metastatic. It metastasizes to the lymph node, lung, pancreas, liver, kidney, and bone, and forms ascites fluid in athymic hosts. ARCaP cells express low levels of androgen receptor mRNA and prostate-specific antigen mRNA and protein. Immunohistochemical staining shows that ARCaP cells stain intensely for epidermal growth factor receptor, c-erb B2/neu, and c-erb B3. Staining is negative for chromogranin A and positive for bombesin, serotonin, neuron- specific enolase, and the c-met protooncogene (a hepatic growth factor/scatter factor receptor). ARCaP cells also secrete high levels of gelatinase A and B and some stromelysin, which suggests that this cell line may contain markers representing invasive adenocarcinoma with selective neuronendocrine phenotypes. Along with its repression of growth, androgen is also found to repress the expression of prostate-specific antigen in ARCaP cells as detected by a prostate-specific antigen promoter-β-galactosidase reporter assay. Our results suggest that the androgen-repressed state may be central to prostate cancer progression and that advanced prostate cancer can progress from an androgen-independent to an androgen-repressed state.",
keywords = "androgen receptor, bone metastasis, gene expression, metalloproteinases, prostate-specific antigen",
author = "Zhau, {Hai Yen E} and Chang, {Shi Ming} and Chen, {Bao Qi} and Yunling Wang and Hongquan Zhang and Chinghai Kao and Sang, {Qingxiang Amy} and Pathak, {Sen J.} and Chung, {Leland W K}",
year = "1996",
month = "12",
day = "24",
doi = "10.1073/pnas.93.26.15152",
language = "English (US)",
volume = "93",
pages = "15152--15157",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "26",

}

TY - JOUR

T1 - Androgen-repressed phenotype in human prostate cancer

AU - Zhau, Hai Yen E

AU - Chang, Shi Ming

AU - Chen, Bao Qi

AU - Wang, Yunling

AU - Zhang, Hongquan

AU - Kao, Chinghai

AU - Sang, Qingxiang Amy

AU - Pathak, Sen J.

AU - Chung, Leland W K

PY - 1996/12/24

Y1 - 1996/12/24

N2 - An androgen-repressed human prostate cancer cell line, ARCaP, was established and characterized. This cell line was derived from the ascites fluid of a patient with advanced metastatic disease. In contrast to the behavior of androgen-dependent LNCaP and its androgen-independent C4-2 subline, androgen and estrogen suppress the growth of ARCaP cells in a dose- dependent manner in vivo and in vitro. ARCaP is tumorigenic and highly metastatic. It metastasizes to the lymph node, lung, pancreas, liver, kidney, and bone, and forms ascites fluid in athymic hosts. ARCaP cells express low levels of androgen receptor mRNA and prostate-specific antigen mRNA and protein. Immunohistochemical staining shows that ARCaP cells stain intensely for epidermal growth factor receptor, c-erb B2/neu, and c-erb B3. Staining is negative for chromogranin A and positive for bombesin, serotonin, neuron- specific enolase, and the c-met protooncogene (a hepatic growth factor/scatter factor receptor). ARCaP cells also secrete high levels of gelatinase A and B and some stromelysin, which suggests that this cell line may contain markers representing invasive adenocarcinoma with selective neuronendocrine phenotypes. Along with its repression of growth, androgen is also found to repress the expression of prostate-specific antigen in ARCaP cells as detected by a prostate-specific antigen promoter-β-galactosidase reporter assay. Our results suggest that the androgen-repressed state may be central to prostate cancer progression and that advanced prostate cancer can progress from an androgen-independent to an androgen-repressed state.

AB - An androgen-repressed human prostate cancer cell line, ARCaP, was established and characterized. This cell line was derived from the ascites fluid of a patient with advanced metastatic disease. In contrast to the behavior of androgen-dependent LNCaP and its androgen-independent C4-2 subline, androgen and estrogen suppress the growth of ARCaP cells in a dose- dependent manner in vivo and in vitro. ARCaP is tumorigenic and highly metastatic. It metastasizes to the lymph node, lung, pancreas, liver, kidney, and bone, and forms ascites fluid in athymic hosts. ARCaP cells express low levels of androgen receptor mRNA and prostate-specific antigen mRNA and protein. Immunohistochemical staining shows that ARCaP cells stain intensely for epidermal growth factor receptor, c-erb B2/neu, and c-erb B3. Staining is negative for chromogranin A and positive for bombesin, serotonin, neuron- specific enolase, and the c-met protooncogene (a hepatic growth factor/scatter factor receptor). ARCaP cells also secrete high levels of gelatinase A and B and some stromelysin, which suggests that this cell line may contain markers representing invasive adenocarcinoma with selective neuronendocrine phenotypes. Along with its repression of growth, androgen is also found to repress the expression of prostate-specific antigen in ARCaP cells as detected by a prostate-specific antigen promoter-β-galactosidase reporter assay. Our results suggest that the androgen-repressed state may be central to prostate cancer progression and that advanced prostate cancer can progress from an androgen-independent to an androgen-repressed state.

KW - androgen receptor

KW - bone metastasis

KW - gene expression

KW - metalloproteinases

KW - prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=0030451767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030451767&partnerID=8YFLogxK

U2 - 10.1073/pnas.93.26.15152

DO - 10.1073/pnas.93.26.15152

M3 - Article

VL - 93

SP - 15152

EP - 15157

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 26

ER -